The announcement of new quantitative PET imaging data on foralumab is a significant development for Tiziana Life Sciences, likely leading to increased investor optimism about the company's research progress and potential market impact. This positive news directly impacts the company's stock price in the short term, as it enhances investor perception and could lead to increased investment.